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Purpose: In epilepsy, many studies were focus on apoE gene polymorphism and found APOE e4 to be
associated with earlier onset of temporal lobe epilepsy. There is not any study about apoE in
cerebrospinal ﬂuid (CSF) of epileptic patients, so we detect the CSF-apoE and determine whether it is
changed after seizure.
Methods: A total of 60 epileptic patients and 28 subjects with no evidence of any neurological diseases
were studied. The concentrations of CSF-apoEwere detectedwith enzyme-linked immunosorbent assay.
Results: The CSF-apoE levels in epilepsy and control group were 5.78  2.15 mg/l and 13.60  12.11 mg/l,
and there were statistical difference. In epilepsy group, the CSF-apoE concentration was 6.53  2.55 mg/l in
male patients, and 4.98  1.21 mg/l in female. In secondary epilepsy group was 5.06  1.31 mg/l, and in
idiopathic epilepsy was 6.04  2.34 mg/l. In different seizure types groups, including complex partial seizure
(CPS), secondarily generalized tonic-clonic seizure (SGTC), generalized tonic-clonic seizure (GTCS), and
absence seizure (AS), the mean concentrations of CSF-apoE were 6.62  3.13 mg/l, 5.21  1.22 mg/l,
5.00  1.09 mg/l and 7.25  1.88 mg/l, respectively.
Conclusions: CSF-apoE concentration decreases after seizures, correlated with the gender, etiological
factor and seizure types.
Crown Copyright  2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Apolipoprotein E (apoE) is a 32 kDa glycoprotein associated
with the lipid transport and metabolism. The human APOE gene
shows polymorphism, with the three different alleles, termed e2,
e3, e4.1 The protein is produced mainly in the liver. However, the
second largest production of apoE is found in the brain, where it is
mostly synthesized by astrocytes and microglia.2,3 ApoE has
special relevance to the lipid metabolism in the nervous tissue. It
plays a central role in modulating learning andmemory, structural
plasticity, mobilization of cholesterol in repair, growth and
maintenance of myelin and neuronal membranes during develop-
ment and aging, and cell death after ischemic, convulsive brain
injury or other brain injury.4–6
Since apoE is involved in the pathogenesis of neurodegenerative
diseases, especially in Alzheimer’s disease (AD).7,8 Numerous
experimental studies have shown that apoE inﬂuences the
majority of the AD pathological processes including amyloid-beta
(Ab) deposition, tangle formation, oxidative stress, lipid homeo-
stasis deregulation, synaptic plasticity loss and cholinergic
dysfunction.5,9–11 In epilepsy, many studies are focus on APOE
gene polymorphism. Gouras et al.12 reported that APOE e4 allele* Corresponding author. Tel.: +86 23 89012878; fax: +86 23 68708697.
E-mail address: xfyp@163.com (X. Wang).
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doi:10.1016/j.seizure.2009.12.001promotes the intracerebral accumulation of b-amyloid in the
patients with temporal lobe epilepsy (TLE); APOE e4 has also been
found to be associated with earlier onset of TLE and cognitive
impairment in TLE.13,14
In our previous study, we compared the cerebrospinal ﬂuid
(CSF) proteome of patients suffering from TLE and the control by
polyacrylamide gel electrophoresis and found apoE expression had
signiﬁcant difference between TLE and control group.15 We
hypothesized that the role of apoE as an important factor in the
response to seizure would be reﬂected by alterations in the
concentration of apoE in the CSF. So we detected the apoE level in
CSF of epileptic patients by enzyme-linked immunosorbent assay
(ELISA).
2. Materials and methods
2.1. Patients
The epilepsy group consisted of 60 patients ranging from 10 to
60 years old (mean  S.D., 28.3  11.6 years) with 31 men and 29
women. All cases were recruited from the epilepsy clinic, department
of Neurology of the First Afﬁliated Hospital of Chongqing Medical
University, betweenMay2008 andApril 2009. All patients underwent
comprehensive clinical examination, including a medical history,
neurological and psychiatric examination, routine laboratory tests,
EEG and brain nuclear magnetic resonance imaging (MRI). Epilepsy. Published by Elsevier Ltd. All rights reserved.
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International League Against Epilepsy in 2001.16 Some patients with
ﬁrst-episode seizure do not have taken any anti-epileptic drugs
(AEDs), others have taken one or more AEDs, including valproic acid,
carbamazepine, topiramate, lamotrigine, and levetiracetam. Table 1
summarized the clinical features as follows.
The control group consisted of 28 subjects ranging from18 to 50
years old (27.2  8.2 years) with 15 men and 13 women with no
evidence of psychiatry or neurological or cardiovascular diseases or
any past history of seizures. All people recruited in the research wereTable 1
The clinical data.
Number Gender Age (year) Age of onset (year) Course of seizure (
1 M 36 33 3
2 M 24 9 15
3 F 49 17 32
4 F 40 21 19
5 M 42 18 24
6 M 18 15 3
7 M 43 21 12
8 M 28 12 16
9 M 18 9 9
10 M 42 40 2
11 M 23 15 8
12 M 33 26 7
13 M 39 38 1
14 F 60 28 32
15 F 46 11 35
16 M 40 16 24
17 F 20 8 12
18 M 40 31 9
19 F 21 10 11
20 M 24 5 9
21 F 34 12 12
22 F 13 9 4
23 M 19 17 2
24 F 22 22 0
25 M 37 37 0
26 M 35 35 0
27 F 51 51 0
28 F 21 21 0
29 M 16 16 0
30 F 13 4 9
31 M 20 16 4
32 M 35 35 0
33 F 39 11 28
34 M 23 23 0
35 M 11 6 5
36 F 27 1 26
37 M 32 16 16
38 F 37 7 30
39 F 37 37 0
40 F 21 14 7
41 M 17 16 1
42 F 29 27 2
43 F 30 30 0
44 F 36 4 32
45 M 41 40 1
46 M 38 30 8
47 M 39 9 30
48 M 17 16 1
49 F 15 15 0.5
50 F 36 26 10
51 F 23 13 10
52 F 13 8 5
53 M 15 10 5
54 F 21 3 18
55 M 14 4 10
56 F 10 3 7
57 F 12 1 11
58 F 25 3 22
59 M 23 7 16
60 F 15 6 9
M, male; F, female; CPS, complex partial seizure; SGTC, secondarily generalized tonic-clo
epileptic drugs; CBZ, carbamazepine; LTG, lamotrigine; TPM, topamax; VPA, valproic aof Chinese origin. The study was approved by the ethics committee of
the First Afﬁliated Hospital of Chongqing Medical University,
Chongqing, China. All epileptic patients and subjects had been given
informed consent to participate in the study, whichwas performed in
accordance with the Helsinki Declaration.
2.2. Samples collection and storage
2 ml CSF was collected from the cases and controls in sterile
polypropylene tubes by lumbar puncture. 1 ml CSF samples sent toyear) Seizure types AEDs Etiological factor
SGTC VPA Unknown
SGTC TPM; CBZ Trauma
CPS CBZ; VPA Unknown
CPS LTG; VPA Unknown
SGTC VPA Unknown
GTCS CBZ Unknown
GTCS VPA Trauma
CPS LTG; VPA Unknown
SGTC TPM; CBZ Unknown
GTCS TPM Unknown
SGTC Traditional Chinese Medicine Unknown
GTCS VPA Unknown
GTCS TMP Trauma
CPS CBZ; VPA Unknown
CPS VPA Unknown
SGTC Traditional Chinese Medicine Encephalitis
GTCS VPA; LTG Encephalitis
GTCS Traditional Chinese Medicine Trauma
CPS VPA; CBZ Trauma
CPS VPA; LTG Unknown
SGTC VPA; LEV Unknown
GTCS CBZ Unknown
SGTC CBZ Unknown
SGTC NO Unknown
GTCS NO Encephalitis
GTCS NO Encephalitis
GTCS NO Encephalitis
GTCS NO Unknown
SGTC NO Unknown
SGTC VPA Trauma
SGTC TPM; CBZ Encephalitis
GTCS NO Unknown
CPS LEV; VPA Encephalitis
GTCS NO Unknown
AS VPA Unknown
CPS VPA; CBZ Unknown
SGTC VPA Trauma
CPS LEV; VPA Unknown
SGTC LTG; VPA Unknown
CPS LTG Unknown
SGTC TPM Unknown
GTCS NO Trauma
SGTC NO Unknown
SGTC CBZ; VPA Unknown
CPS NO Unknown
SGTC LTG Trauma
CPS LEV; VPA Unknown
CPS LEV Unknown
CPS NO Unknown
SGTC TPM Unknown
CPS VPA Unknown
AS LTG; VPA Unknown
SGTC LTG Unknown
CPS VPA; LEV Unknown
AS VPA Unknown
AS VPA Unknown
AS LTG; VPA Unknown
SGTC TPM; CBZ Unknown
CPS VPA; TLG Unknown
AS LTG; VPA Unknown
nic seizure; GTCS, generalized tonic-clonic seizure; AS, absence seizure; AEDs, anti-
cid; LEV, levetiracetam.
Table 2
The demographic characteristics of subjects.
EP (n=60) Control (n=28) Results
Age (years) 28.311.6 27.28.2 p>0.05
Gender
Female 29 (48.3%) 13 (46.4%) p>0.05
Male 31 (51.7%) 15 (53.6%)
EP, epilepsy.
Table 3
The concentration of CSF-apoE and total protein in epileptic patients and controls.
EP (n=60) Control (n=28)
CSF-apoE (mg/l) 5.782.15* 13.612.11
Total protein (mg/l) 27083.3 267.165.9
EP, epilepsy.
* p<0.05.
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biochemistry analysis, and 1 ml samples were centrifuged at
500  g (2000 rpm) for 10 min at 4 8C in refrigerated centrifuge
(Sigma, USA) to separate cell component, and then CSF samples
were divided into ﬁve parts in average and rapidly frozen and
stored at 80 8C for later analysis.
2.3. Enzyme-linked immunosorbant assays
CSF-apoE was determined using ELISA, with Human apolipo-
protein E Elisa Kit (Uscn Life Science & Technology Company,
Wuhan, China). Add 100 ml of standard, blank, and samples (CSF
samples were undiluted) in per well and incubate for 2 h at 37 8C
coveringwith plate sealer. Then remove the liquid of eachwell and
add 100 ml detection reagent A working solution to each well and
incubate for 1 h at 37 8C, and then aspirate each well and wash by
ﬁlling each well with wash buffer using multichannel pipettor,
repeating the process three times. After that, add 100ml detection
reagent A working solution to each well and incubate for 1 h at
37 8C and repeat the aspirate and wash steps. Then add 90 ml
substrate solution to each well and incubate for 30 min at 37 8C,
protecting from light. Add 50 ml stop solution to each well, if color
change does not appear uniform. Finally, determine the optical
density of each well at once, using a microplate reader set to
450 nm on Multiscan Spectrum Microplate Spectrophotometer
(Thermo Fisher Scientiﬁc, USA).
2.4. Statistical analysis
Descriptive data were computed using means  standard
deviation (S.D.). The analysis was carried out using independent
sample t-test and one-way analysis of variance (ANOVA). In the study,
p value < 0.05 was considered signiﬁcant. Statistical analysis was
done using SPSS statistics 10.0.Fig. 1. The concentration of CSF-apoE in male and female patients (A), in idiopathic ep
p < 0.05.3. Results
In our study, the age of epileptic patients at seizure onset was
from 1 to 51 years old, and the mean age was 17.8 years old. The
duration of disease was between 0 and 35 years, and mean
duration was 10.4 years. 16.7% patients were suffered from ﬁrst-
episode seizure, 25% patients had not so many as a 5 years history
of seizures, and 68.3% had a clinical history of more than 5 years;
20% patients did not have taken any AEDs and 80% patients had
taken one or more kinds of AEDs; 73.3% patients were idiopathic
epilepsy, while 26.7% were secondary epilepsy, including second-
ary to trauma and encephalitis; In terms of seizure types, 30%
patients were complex partial seizure (CPS), 35% were secondarily
generalized tonic-clonic seizure (SGTC), 25% were generalized
tonic-clonic seizure (GTCS), and 10% were absence seizure (AS).ilepsy and secondary epilepsy group (B), and in different seizure types groups (C).
Fig. 2. The concentration of CSF-apoE in different age of seizure onset (A), in different course of disease (B), and in taking or not taking AEDs groups (C). Therewas no statistical
difference.
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subjects that participated in this study. There were no signiﬁcant
differences in age or sex of subjects between epilepsy and control
group.
CSF-apoE concentration in epilepsy group was 5.78 2.15 mg/l,
and was approximately two-fold lower than that of controls
(13.60 12.11 mg/l), and this difference was statistically signiﬁcant
(p < 0.05). The concentration of total protein in towgroupswas similar
(Table 3). In epilepsy group, the concentrations of CSF-apoE were
6.53  2.55 mg/l in male patients and 4.98 1.21 mg/l in female, and
there were statistical difference (p < 0.05) (Fig. 1A). Themean levels of
CSF-apoE in patients whose seizure onset age before 10, 10–20, and
after 20 years old, were 5.67  2.25 mg/l, 5.59  1.96 mg/l and
6.09  2.31 mg/l, respectively (p < 0.05) (Fig. 2A). In different duration
of disease groups, including ﬁrst-episode seizure group
(5.98 2.18 mg/l), 5 years group (5.68  1.57 mg/l) and >5 years
group (5.77 2.39 mg/l), there were no statistical difference (Fig. 2B).
The concentrations of CSF-apoE were 5.97 1.88 mg/l and
5.73  2.22 mg/l in no AEDs taking group and AEDs taking group,
there were no statistical difference (Fig. 2C). CSF-apoE in secondary
epilepsy group (5.06  1.31 mg/l) was lower than that in idiopathic
epilepsy (6.04  2.34 mg/l) (p < 0.05) (Fig. 1B). In different seizure
types groups, the mean concentrations of CSF-apoE were
6.62  3.13 mg/l (CPS), 5.21  1.22 mg/l (SGTC), 5.00  1.09 mg/l
(GTCS) and 7.25 1.88 mg/l (AS), in SGTS and GTCS groups CSF-apoE
levels were lower than that in CPS and AS groups (p < 0.05) (Fig. 1C).
4. Discussion
The main ﬁnding of our study is that the concentration of CSF-
apoE of epileptic patients is substantially lower than non-seizure
controls. This trend of CSF-apoE level is also detected in AD and
traumatic brain injury.A possible explanation for the decreased concentration of CSF-
apoE after seizure would be uptake by cells in contact with the
CSF. Lipoprotein receptors are present in the ependymal cells
lining the ventricular space, or astrocytes adjacent to the
arachnoid space, and the cells of the arachnoid itself.17,18 Evidence
from some studies supports the hypothesis that there is an
increase in human and rats brain apoE after injury. In studies of
brain tissue excision from patients undergoing surgery for
medical intractable epilepsy, and postmortem material taking
from Alzheimer’s disease patient, strong apoE immunoreactivity
was observed in many astrocytes and some cortical neurons.19–21
Experimental seizure models induced by kainate identiﬁed
increased apoE expression in hippocampus, this observation
indicates that lipidic metabolism is modiﬁed in the lesioned
structure and suggests an increased trafﬁc of lipids and a need for
more apoE in the hippocampus during the period of recovery and
restructuration that follows severe seizures.22 Thus CSF-apoEmay
be transported to the intracellular compartment and play an
important role in themaintenance and repair of neurons. A further
contributory factor diminishing the concentration of CSF-apoE
after seizures might be decreased apoE synthesis in response to
seizure. In vitro studies report reduced apoE levels in astrocyte
culture medium in response to pro-inﬂammatory cytokines,
which are known to be elevated after epileptic attack and other
neurological disorders.23–26
The concentration of CSF-apoE is correlated to gender. It may be
related with estrogen, which has been shown to increase apoE
levels in rat brain in vivo and in astrocytes and mixed glia cultures
in vitro.27,28 In our study, we found the CSF-apoE levels had
statistical difference between secondary epilepsy and idiopathic
epilepsy. Seizures after traumatic brain injury and encephalitis are
common secondary epilepsy, before epileptic attack, there have
been neuronal necrosis. The concentration of apoE in CSF of
L. Wang et al. / Seizure 19 (2010) 79–83 83patients with severe traumatic brain injury and subarachnoid
hemorrhage is lower than controls and correlation with injury
severity.29,30 We also found the CSF-apoE levels were correlated
with the seizure types, when patients were suffering from SGTC
and GTCS, their brain would be in hypoxia ischemia brain damage
state.31 The decrease of CSF-apoE after seizure might be related
with the brain injury severity.
Some studies detected a statistically signiﬁcant result between
an early age at onset of TLE and the presence of the APOE e4
allele.13,14 But our study did not ﬁnd any association between CSF-
apoE and age of seizure onset. The concentration of CSF-apoE is not
also related with duration of seizure and taking AEDs or not. These
results suggest that CSF-apoE levels decreasing in epileptic
patients might be a phenomenon responsing to seizures, not the
reason causing epileptic attack.
In conclusion, decreased concentration of CSF-apoE in epileptic
patients has been observed for the ﬁrst time, and is correlatedwith
the gender, etiological factor and seizure types. Further studies on
the status of apoE levels in a larger number of epileptic patients
with regularly follow-up would enable us to understand the
possible role of apoE in epilepsy.
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